All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-08-06T08:19:47.000Z

What are the latest treatment advances for Hodgkin lymphoma?

By Camilla Rossi, Erika Roa, Quintina Dawson
Featured
Alison Moskowitz
Aug 6, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in Hodgkin lymphoma.

Bookmark this article

During the 2022 ASCO Annual Meeting, the Lymphoma Hub spoke with Alison Moskowitz, Feinstein Institutes for Medical Research, New York, US. We asked, What are the latest treatment advances for Hodgkin lymphoma?

What are the latest treatment advances for Hodgkin lymphoma?

Moskowitz begins by discussing the evolution of treatment for Hodgkin lymphoma and the impact positron emission tomography (PET)-adapted therapy has had in the field. Moskowitz outlines recent studies and new therapies that are significantly changing the treatment landscape.

 

More about...
ASCO 2022Hodgkin lymphoma

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Treating classical Hodgkin lymphoma that is refractory to salvage chemotherapy

As part of our biannual steering committee meeting, Astrid Pavlovsky, Fundaleu, Beunos Aires, AR, chaired a case study discussion session on treating a patient with...

Jul 27, 2022
Add bookmark

Treating classical Hodgkin lymphoma that is refractory to salvage chemotherapy

As part of our biannual steering committee meeting, Astrid Pavlovsky, Fundaleu, Beunos Aires, AR, chaired a case study...

Jul 27, 2022
Add bookmark

What is on the horizon for the frontline treatment of MCL?

During the ASCO 2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the...

Jul 25, 2022
Add bookmark

What is on the horizon for the frontline treatment of MCL?

During the ASCO 2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York,...

Jul 25, 2022

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox